bullish
Dr Lal PathLabs Ltd (DLPL IN): Volume Driven Topline Growth and Margin Improvement Continued in Q2
345 Views24 Oct 2024 22:21
SUMMARY
- Dr Lal PathLabs Ltd (DLPL IN) reported 10% revenue growth in Q2, driven by volume. The bottomline surge of 18% has again outpaced revenue growth, resulting in margin expansion.
- There has been a significant improvement in Suburban’s revenue growth rate at 12%, with EBITDA margin reaching 20%. The company maintained 10% revenue growth target for the current financial year.
- The operating environment is becoming conducive. Competitive intensity in terms of predatory pricing, promotional offer, and cash burning to acquire customers, have come to an end.
Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
- Unlock research summaries
- Follow top, independent analysts
- Receive personalised alerts
- Access Analytics, Events and more
Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.
Upgrade later to our paid plans for full-access.
or
Already have an account? Sign In Now
Discussions
(Paid Plans Only)
Top Quartile
Tina Banerjee
Global Healthcare Analyst
Price Chart(Sign Up to Access)
- Dr Lal PathLabs Ltd (DLPL IN): Poised for Next Level of Growth Amid Easing Price Competition02 Oct 2024
- Dr Lal PathLabs (DLPL IN): Strong Trajectory in Non-COVID Business; Positive Industry Outlook11 Jul 2023
- Dr Lal PathLabs (DLPL IN): Losing Path Amid Competition; Non-COVID Growth Underwhelming30 Mar 2023
x